Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsTo evaluate the tolerance and efficacy of prophylactic donor lymphocyte infusion in patients with unfavourable gene mutations such as FLT3‐ITD, TP53, ASXL1, DNMT3A or TET2, scientists performed a prospective, single‐arm study.
[Cancer Medicine]
6445218 {6445218:7IDF82S5} apa 50 1 161865 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-cb66357fee4c68170d16349778806803%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%227IDF82S5%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EZhang%2C%20R.%2C%20Wang%2C%20L.%2C%20Chen%2C%20P.%2C%20Gao%2C%20X.%2C%20Wang%2C%20S.%2C%20Li%2C%20F.%2C%20Dou%2C%20L.%2C%20Gao%2C%20C.%2C%20Li%2C%20Y.%2C%20%26amp%3B%20Liu%2C%20D.%20%28n.d.%29.%20Haematologic%20malignancies%20with%20unfavourable%20gene%20mutations%20benefit%20from%20donor%20lymphocyte%20infusion%20with%5C%2Fwithout%20decitabine%20for%20prophylaxis%20of%20relapse%20after%20allogeneic%20HSCT%3A%20A%20pilot%20study.%20%3Ci%3ECancer%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3En%5C%2Fa%3C%5C%2Fi%3E%28n%5C%2Fa%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.3763%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2Fhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.3763%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3D7IDF82S5%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Haematologic%20malignancies%20with%20unfavourable%20gene%20mutations%20benefit%20from%20donor%20lymphocyte%20infusion%20with%5C%2Fwithout%20decitabine%20for%20prophylaxis%20of%20relapse%20after%20allogeneic%20HSCT%3A%20A%20pilot%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rui%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lili%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaoning%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuhong%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fei%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liping%22%2C%22lastName%22%3A%22Dou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chunji%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daihong%22%2C%22lastName%22%3A%22Liu%22%7D%5D%2C%22abstractNote%22%3A%22Relapse%20is%20the%20main%20cause%20of%20treatment%20failure%20for%20leukaemia%20patients%20with%20unfavourable%20gene%20mutations%20who%20receive%20allogeneic%20haematopoietic%20stem%20cell%20transplantation%20%28allo-HSCT%29.%20There%20is%20no%20consensus%20on%20the%20indication%20of%20donor%20lymphocyte%20infusion%20%28DLI%29%20for%20prophylaxis%20of%20relapse%20after%20allo-HSCT.%20To%20evaluate%20the%20tolerance%20and%20efficacy%20of%20prophylactic%20DLI%20in%20patients%20with%20unfavourable%20gene%20mutations%20such%20as%20FLT3-ITD%2C%20TP53%2C%20ASXL1%2C%20DNMT3A%20or%20TET2%2C%20we%20performed%20a%20prospective%2C%20single-arm%20study.%20Prophylactic%20use%20of%20decitabine%20followed%20by%20DLI%20was%20planned%20in%20patients%20with%20TP53%20or%20epigenetic%20modifier%20gene%20mutations.%20The%20prophylaxis%20was%20planned%20in%2046%20recipients%3A%20it%20was%20administered%20in%2028%20patients%20and%20it%20was%20not%20administered%20in%2018%20patients%20due%20to%20contraindications.%20No%20DLI-associated%20pancytopenia%20was%20observed.%20The%20cumulative%20incidences%20of%20grade%20II%5Cu2013IV%20and%20III%5Cu2013IV%20acute%20graft-versus-host%20disease%20%28GVHD%29%20at%20100%20days%20post-DLI%20were%2025.8%25%20and%2011.0%25%2C%20respectively.%20The%20rates%20of%20chronic%20GVHD%2C%20non-relapse%20mortality%20and%20relapse%20at%203%20years%20post-DLI%20were%2021.6%25%2C%2025.0%25%20and%2026.1%25%2C%20respectively.%20The%203-year%20relapse-free%20survival%20and%20overall%20survival%20%28OS%29%20rates%20were%2048.9%25%20and%2048.2%25%2C%20respectively.%20Acute%20GVHD%20%28HR%3A%202.30%2C%20p%20%3D%200.016%29%20and%20relapse%20%28HR%3A%202.46%2C%20p%20%3D%200.003%29%20after%20DLI%20were%20independently%20associated%20with%20inferior%20OS.%20Data%20in%20the%20current%20study%20showed%20the%20feasibility%20of%20prophylactic%20DLI%20with%5C%2Fwithout%20decitabine%20in%20the%20early%20stage%20after%20allo-HSCT%20in%20patients%20with%20unfavourable%20gene%20mutations.%22%2C%22date%22%3A%22%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.3763%22%2C%22ISSN%22%3A%222045-7634%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fcam4.3763%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-05-04T17%3A45%3A43Z%22%7D%7D%5D%7D
Zhang, R., Wang, L., Chen, P., Gao, X., Wang, S., Li, F., Dou, L., Gao, C., Li, Y., & Liu, D. (n.d.). Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study. Cancer Medicine, n/a(n/a). https://doi.org/https://doi.org/10.1002/cam4.3763 Cite
